Treatment of Tinnitus With Migraine Medications
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04404439 |
|
Recruitment Status :
Recruiting
First Posted : May 27, 2020
Last Update Posted : January 9, 2023
|
Sponsor:
University of California, Irvine
Information provided by (Responsible Party):
Hamid Djalilian, University of California, Irvine
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
Tinnitus represents one of the most common and distressing otologic problems, and it causes various somatic and psychological disorders that interfere with the quality of life. It is well-understood that many factors, such as poor education, lower income, or occupational, and recreational activity associated with high noise exposure, influences the prevalence and risk of tinnitus. Although the economic and emotional impact of tinnitus is large, there is currently no FDA-approved medication to treat this condition. However, there are pharmacological options to address the stress, anxiety, and depression that are caused by tinnitus. In this project, we intend to use medications for patients with tinnitus in order to decrease the impact of tinnitus on their daily life and activities.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Tinnitus, Subjective Tinnitus | Drug: Nortriptyline + topiramate Drug: Verapamil + paroxetine Other: Placebo | Phase 4 |
This study is 8 weeks in duration. There are three arms in the experiment: the first is nortriptyline (7.5 mg) plus topiramate (10 mg), the second is verapamil (30 mg) plus paroxetine (4 mg), and the third is a placebo group. This is a double-blinded trial. Participants will be randomized to one arm for the duration of the trial using simple randomization with a computer-generated number. Both medication combinations and placebo may include dosage increases weekly if symptoms do not improve. Nortriptyline may be increased by 7.5mg weekly (to a maximum of 60mg), topiramate by 10mg weekly (maximum 80mg), verapamil by 30mg weekly (maximum 240mg), and paroxetine by 4mg weekly (maximum 32mg). Symptomatic survey scores from each arm will be obtained before and after treatment and weekly. An unblinded neurotologist attending (Dr. Harrison Lin) will also become involved with patients' treatments as they start to report changes in symptoms in order to monitor their safety and provide advice on change in dosage if patients have questions.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 150 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | Participants will be assigned to a study group by chance (like a coin flip) rather than by a medical decision made by the researchers. There are three arms in the study (treatment group 1 which consists of nortriptyline + topiramate, treatment group 2 which consist of verapamil + paroxetine, and a placebo group), and participants enrolling in the trial will be randomly assigned in a 1:1:1 fashion to one of the arms. The participant will remain in the same arm for the duration of the study (8 weeks). There may be multiple participants in each arm who are undergoing the study at the same time (parallel model). |
| Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | Treatment of Tinnitus With Migraine Medications: A Randomized Clinical Trial |
| Actual Study Start Date : | September 26, 2019 |
| Estimated Primary Completion Date : | December 30, 2023 |
| Estimated Study Completion Date : | December 30, 2023 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Migraine
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Nortriptyline + topiramate
Nortriptyline (7.5 mg) plus topiramate (10 mg) in a single pill initially taken once daily. Dose may be increased as directed by care provider by 7.5mg weekly (to a maximum of 60mg) for nortriptyline, and by 10mg weekly (maximum 80mg) for topiramate.
|
Drug: Nortriptyline + topiramate
Treatment group 1 |
|
Experimental: Verapamil + paroxetine
Verapamil (30 mg) plus paroxetine (4 mg) in a single pill initially taken once daily. Dose may be increased as directed by care provider by 30mg weekly (to a maximum of 240mg) for verapamil, and by 4mg weekly (maximum 32mg) for paroxetine.
|
Drug: Verapamil + paroxetine
Treatment group 2 |
|
Placebo Comparator: Placebo
Placebo pill.
|
Other: Placebo
Placebo comparator |
Primary Outcome Measures :
- Tinnitus Functional Index (TFI) [ Time Frame: 8 weeks ]Subjective improvement from baseline in tinnitus symptoms as measured by Tinnitus Functional Index (TFI). The TFI is scored from 0% to 100%, with higher scores indicating a more negative impact of tinnitus.
Secondary Outcome Measures :
- Visual Analog Scale (VAS) [ Time Frame: 8 weeks ]Subjective improvement in tinnitus loudness severity based on a visual analog scale (VAS). The VAS is scored from 0 to 10, with a higher score representing an increased severity of tinnitus.
- Patient Health Questionnaire (PHQ) [ Time Frame: 8 weeks ]Subjective improvement in depression symptoms based on patient health questionnaire (PHQ). The PHQ is scored from 0 to 27, with a higher score indicating increased depression severity.
- Perceived Stress Scale (PSS) [ Time Frame: 8 weeks ]Subjective improvement in stress based on perceived stress scale (PSS). The PSS is scored from 0 to 40, with higher scores indicating higher perceived stress.
- Sleep Quality Index (SQI) [ Time Frame: 8 weeks ]Subjective improvement in sleep quality based on sleep quality index (SQI). The SQI is scored from 0 to 21, with higher scores indicating worse quality of sleep.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 25 Years to 85 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patients with moderate to severe tinnitus.
- Male or female between the ages of 25 to 85 years.
- Subject must be compliant with the medication and attend study visits.
- Must be able to read and write in the English language to provide consenting.
Exclusion Criteria:
- Pregnancy will result in automatic exclusion from the study. Rule out of pregnancy will be done by a urine pregnancy test to confirm the situation for all women who are of child bearing potential.
- Subject with history of an adverse reaction to medication being prescribed.
- Subject suffers from a medical condition or has history that may be concerning to the investigators clinical opinion.
- All contraindications for the medications which prevent subjects from randomization will be considered as exclusion criteria.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04404439
Contacts
| Contact: Hamid R Djalilian, MD | 800-263-9547 | hdjalili@hs.uci.edu |
Locations
| United States, California | |
| University of California, Irvine Medical Center ENT Clinic (Pavilion 2) | Recruiting |
| Orange, California, United States, 92868 | |
| Contact: Hamid R Djalilian, MD 800-263-9547 hdjalili@hs.uci.edu | |
| Contact: Mehdi Abouzari, MD, PhD 714-509-6096 mabouzar@hs.uci.edu | |
| Principal Investigator: Hamid R Djalilian, MD | |
| Sub-Investigator: Mehdi Abouzari, MD, PhD | |
Sponsors and Collaborators
University of California, Irvine
Investigators
| Principal Investigator: | Hamid R Djalilian, MD | Univeristy of California, Irvine |
Publications:
| Responsible Party: | Hamid Djalilian, Professor, Neurotology and Skull Base Surgery, University of California, Irvine |
| ClinicalTrials.gov Identifier: | NCT04404439 |
| Other Study ID Numbers: |
HS# 2018-4458 |
| First Posted: | May 27, 2020 Key Record Dates |
| Last Update Posted: | January 9, 2023 |
| Last Verified: | January 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
| Product Manufactured in and Exported from the U.S.: | No |
Keywords provided by Hamid Djalilian, University of California, Irvine:
|
tinnitus medication randomized |
RCT trial migraine |
Additional relevant MeSH terms:
|
Tinnitus Migraine Disorders Headache Disorders, Primary Headache Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Hearing Disorders Ear Diseases Otorhinolaryngologic Diseases Sensation Disorders Neurologic Manifestations Topiramate Verapamil Paroxetine |
Nortriptyline Anticonvulsants Hypoglycemic Agents Physiological Effects of Drugs Selective Serotonin Reuptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Neurotransmitter Agents Serotonin Agents Antidepressive Agents, Second-Generation Antidepressive Agents Psychotropic Drugs Cytochrome P-450 CYP2D6 Inhibitors Cytochrome P-450 Enzyme Inhibitors |